We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+17.47%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.02B
AUM Growth
+$399M
Cap. Flow
+$261M
Cap. Flow %
8.64%
Top 10 Hldgs %
52.67%
Holding
175
New
36
Increased
34
Reduced
22
Closed
43

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$50.4M
2
LJPC
La Jolla Pharmaceutical Company
LJPC
+$40.2M
3
MMSI icon
Merit Medical Systems
MMSI
+$32.5M
4
ABMD
Abiomed Inc
ABMD
+$30.5M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$24.6M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$57.5M
2
NXTM
NxStage Medical Inc.
NXTM
+$34.9M
3
TSRO
TESARO, Inc.
TSRO
+$25.4M
4
PBYI icon
Puma Biotechnology
PBYI
+$24.6M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$19.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.12%
2 Consumer Discretionary 0.06%
3 Technology 0.04%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VNDA icon
151
Vanda Pharmaceuticals
VNDA
$304M
– –
-36,232
Closed -$649K
VYGR icon
152
Voyager Therapeutics
VYGR
$181M
– –
-34,604
Closed -$712K
ITCI
153
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-929,460
Closed -$14.7M
IMGN
154
DELISTED
Immunogen Inc
IMGN
– –
-70,126
Closed -$536K
ICPT
155
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-250,000
Closed -$283K
ICPT
156
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-90,000
Closed -$5.22M
ZYNE
157
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
– –
-130,700
Closed -$1.32M
PRTK
158
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
– –
-21,186
Closed -$532K
VIVE
159
DELISTED
VIVEVE MED INC
VIVE
– –
-487
Closed -$2.55M
INOV
160
DELISTED
Inovalon Holdings, Inc. Class A Common Stock
INOV
– –
-30,000
Closed -$511K
PRAH
161
DELISTED
PRA Health Sciences, Inc.
PRAH
– –
-7,427
Closed -$566K
GWPH
162
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-36,763
Closed -$3.73M
NBRV
163
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
– –
-210
Closed -$431K
PTLA
164
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-7,870
Closed -$425K
ONCE
165
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
– –
-180,000
Closed -$16M
AKAO
166
DELISTED
Achaogen Inc
AKAO
– –
-27,551
Closed -$439K
CMTA
167
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
– –
-352,250
Closed -$6.29M
NXTM
168
DELISTED
NxStage Medical Inc.
NXTM
– –
-1,264,523
Closed -$34.9M
ATHN
169
DELISTED
Athenahealth, Inc.
ATHN
– –
-70,000
Closed -$8.71M
MGCD
170
DELISTED
MGC Diagnostics Corporation
MGCD
– –
-252,327
Closed -$2.26M
OCRX
171
DELISTED
Ocera Therapeutics, Inc.
OCRX
– –
-2,038,880
Closed -$2.32M
HSKA
172
DELISTED
Heska Corp
HSKA
– –
-7,300
Closed -$643K
3 4 5 6
7

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q4 2017 Portfolio in Review

As of Q4 2017, Perceptive Advisors held 175 positions worth $3.02B, up 15% from $2.62B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Perceptive Advisors deployed $261M of net new capital in Q4 2017, opening 36 new positions and adding to 34 existing holdings. Its largest new stake was Zimmer Biomet: 206,000 shares worth $24.1M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $57.5M trimmed.

  • Perceptive Advisors's largest Q4 2017 buy was Zimmer Biomet: 206,000 shares worth $24.1M.
  • Perceptive Advisors added most to Blueprint Medicines in Q4 2017, an estimated $50.4M increase.
  • Perceptive Advisors's biggest Q4 2017 reduction was Alnylam Pharmaceuticals, cutting an estimated $57.5M.
  • Perceptive Advisors fully exited NxStage Medical Inc. in Q4 2017, selling an estimated $34.9M.
  • Perceptive Advisors's ten largest holdings make up 53% of its $3.02B portfolio in Q4 2017.
  • Perceptive Advisors opened 36 new positions and closed 43 in Q4 2017.
  • Perceptive Advisors's portfolio value rose 15% quarter-over-quarter to $3.02B.

Based on Perceptive Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.